ASCO GI 2025: Danish Study Highlights Efficacy and Safety of Single-Cycle Neoadjuvant Pembrolizumab for Localized dMMR Colon Cancer
Findings from the RESET-C study suggest that a single cycle of neoadjuvant pembrolizumab offers high efficacy and manageable safety for patients with localized dMMR colon cancer, as presented at the ASCO Gastrointestinal Cancers Symposium.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in